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A contaminant protein complex found in pharmaceutical
urinary human chorionic gonadotrophin preparations is
reported to have anti-human immunodeficiency virus-as-
sociated Kaposi’s sarcoma activity. The aim of this
study was to isolate and characterize this protein com-
plex by proteomic approaches. Size exclusion chroma-
tography was used in the isolation of these human cho-
rionic gonadotrophin-associated fragments. Sodium
dodecyl sulfate-polyacrylamide gel electrophoresis
showed the presence of a protein complex that disso-
ciated into two protein bands under reducing condi-
tions. Matrix-assisted laser desorption/ionization time-
of-flight mass spectrometry of this complex showed
three polypeptides at 6.2, 11.4, and 15.8 kDa. Peptide
mass mapping and N-terminal amino acid sequencing
identified two polypeptides as metabolites of placental
transforming growth factor- (11.4 kDa) and bikunin
(15.8 kDa). Subsequent matrix-assisted laser desorp-
tion/ionization time-of-flight mass spectrometric analysis
of the anti-human immunodeficiency virus-associated
Kaposi’s sarcoma active preparations CG-10 (Sigma),
Pregnyl (Organon), and Profasi (Serono) revealed the
presence of metabolites of placental transforming growth
factor- in all three; no other non-human chorionic gona-
dotrophin-related protein species were observed in these
preparations. Our findings present evidence that urinary
human chorionic gonadotrophin preparations are con-
taminated with metabolites of placental transforming
growth factor-, which may have transforming growth
factor- agonist actions, and metabolites of bikunin,
which is a protease inhibitor. In combination these mol-
ecules may be responsible for the anti-human immuno-
deficiency virus-associated Kaposi’s sarcoma activity
demonstrated for these urinary human chorionic gonad-
otrophin preparations. Molecular & Cellular Proteom-
ics 4:984–992, 2005.
Human chorionic gonadotrophin (hCG)1 is the principal hor-
monal product of the conceptus and is responsible for sig-
naling maternal recognition of pregnancy in humans. More
recently it has been reported to inhibit human immunodefi-
ciency virus (HIV) replication in maternal blood cells during
pregnancy and transmission from lymphocytes to tropho-
blasts (1). It was later proposed that the antiviral activity of
hCG in blood cells was determined by its free -subunit
(hCG) (2). The anti-HIV effects of hCG and hCG have also
been noted in HIV-associated Kaposi’s sarcoma (KS) (3–7).
KS usually presents as lesions consisting of aggregates of
spindle-shaped cells interspersed with endothelium-lined
channels, which remain confined to the subcutaneous layer of
the skin. Human hepatitis virus-8 is the main causative agent
of KS, but HIV infection results in a completely distinct man-
ifestation; lesions arise all over the body but particularly affect
the face and the moist mucosa of the mouth and nose (8).
HIV-induced KS is the most common tumor of patients in-
fected with the virus, and the risk of developing the sarcoma
is increased 20,000-fold in acquired immunodeficiency syn-
drome sufferers (8). The anti-HIV-KS activity of hCG was
initially noted as part of an investigation into the significance
of the male gender bias of HIV-associated KS: Kaposi ob-
served a bias of 15:1 toward male presentation for this con-
dition in his initial study (for a review, see Ref. 9). Lunardi-
Iskandar et al. (4) at the NCI, National Institutes of Health
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(Bethesda, MD) noticed that mice with induced KS who then
became pregnant went into tumor remission. They went on to
describe how preparations of hCG and hCG “killed KS cells
in vitro and in vivo, apparently by apoptosis.” The effect was
initially attributed to luteinizing hormone/hCG receptor activa-
tion, but the mouse does not possess a chorionic gonadotro-
phin  gene or express an equivalent gonadotrophin during
pregnancy (10). Various clinical trials were carried out; most of
them used crude hCG preparations. In the majority of studies,
hCG administration resulted in various degrees of KS lesion
remission (11–17). In response to this, Krown (18) commented
on the variation in the quality of hCG preparations; the free
subunits of hCG and the urinary metabolite of hCG, hCG
core fragment (hCGcf), were common contaminants. Rabkin
et al. (19) suggested that a contaminant factor present in
pregnancy urine hCG must explain the tumor regression in
pregnant mice. Albini et al. (20) concluded that the active
compound was hCGcf. However, others fractionating anti-
HIV-KS active hCG preparations suggested that the anti-
HIV-KS activity was due to small contaminating molecules
that eluted close to hCGcf on size exclusion columns (21).
Various low molecular weight components have now been
isolated from neat pregnancy urine and urinary hCG prepara-
tions with anti-HIV-KS activity. These have been variously
described as antiviral lysozyme C and antiviral RNases (22–
24). However, none have been unequivocally identified and
are best described as an unidentified protein complex termed
“hCG-associated fragments” (HAF) (25, 26).
We have previously isolated and purified a contaminant
complex of the urinary hCG preparation CG-10 (Sigma) that
appeared to co-elute in our isolation of hCGcf (27). We now
report the characterization of this protein complex by SDS-
PAGE, N-terminal sequencing, and mass spectrometry and
confirm its presence in urinary hCG preparations found to
have anti-HIV-KS activity.
EXPERIMENTAL PROCEDURES
Reagents—Three clinical grade hCG preparations were used:
CG-10 (Sigma), Pregnyl (Organon, Cambridge, UK), and Profasi (Se-
rono, Feltham, UK). The MALDI-TOF MS grade matrices -cyano-4-
hydroxycinnamic and 2,5-dihydroxybenzoic acids were obtained
from Fluka (Poole, UK). All other chemicals were obtained from Merck
unless otherwise stated.
Size Exclusion Chromatography—HAF was isolated from CG-10 by
size exclusion chromatography on a Sephadex G-100 column (Am-
ersham Biosciences) as described previously (27). Briefly the material
was dissolved in 0.01 M phosphate buffer saline prior to chromatog-
raphy. The column was then eluted with the above buffer.
Assays—Total protein was measured by using the Bradford dye
(0.5 mg/ml Coomassie Blue G in 25% ethanol, 42.5% concentrated
phosphoric acid). Absorbance was read at 570 nm by using an
EL311SX microtiter plate reader (Anachem, Luton, UK).
The S781 polyclonal antibody was used as the capture antibody
against intact hCG, whereas the S752 monoclonal antibody was used
as the capture antibody against free hCG (27). The M107 monoclonal
antibody (27) was conjugated to horseradish peroxidase (Dako, Ely, UK)
and was subsequently used as the detection antibody in both assays.
The INN112 monoclonal antibody was used as a capture antibody
against the 13 epitope on hCGcf; the INN112 antibody was a gift
from Professor Peter Berger (Institute for Biomedical Aging Research,
Innsbruck, Austria). The S504 polyclonal antibody (27) was used as a
primary detection antibody for hCGcf, and a donkey anti-sheep-
horseradish peroxidase monoclonal antibody (Jackson Immunore-
search Inc., West Grove, PA) was used as a secondary detection
antibody.
SDS-PAGE—One-dimensional SDS-PAGE was performed using
20% acrylamide separating gels and 5% stacking gels. Samples were
denatured for 5 min at 100 °C prior to running under reducing and
non-reducing conditions. Electrophoresis was performed in Tris-gly-
cine buffer at a constant current of 15 mA. Gels were stained over-
night with 25% Coomassie Blue (w/v) in 50% methanol, 10% acetic
acid and destained with 50% methanol, 10% acetic acid.
In Situ Reduction, Alkylation, and Digestion—Reduction and alky-
lation of the stained proteins were done with dithiothreitol and iodoac-
etamide as described previously (28). Briefly stained protein bands
were excised from gels and were further destained with 25 mM
ammonium bicarbonate, 50% acetonitrile and reduced and alkylated
with 10 mM dithiothreitol and 55 mM iodoacetamide. Tryptic digestion
was carried out at a concentration of 12.5 ng/l trypsin (Sigma) in a
solution of 50 mM ammonium bicarbonate, 5 mM calcium chloride.
MALDI-TOF MS—A sample preparation protocol using MALDI tar-
get plates with a 600-m hydrophilic anchor (AnchorChipTM 600,
Bruker Daltonics, Coventry, UK) was used (29). All protein prepara-
tions and in-gel tryptic digests were desalted using C18 ZipTips
(Millipore). An aliquot of the sample was acidified with 1 l of 1%
aqueous trifluoroacetic acid to enhance peptide binding on the C18
resin. Conditioning, loading, and washing steps were done according
to the manufacturer’s recommendation. Proteins and peptides were
eluted from the C18 bed with 2 l of acetonitrile, 0.1% aqueous
trifluoroacetic acid (50:50, v/v) directly onto either a thin layer of
-cyano-4-hydroxycinnamic acid crystals formed from 0.3 l of a 5
mg/ml solution of -cyano-4-hydroxycinnamic acid (acetone, 0.1%
aqueous trifluoroacetic acid; 97:3) or a thin layer of 2,5-dihydroxy-
benzoic acid crystals formed from 0.5 l of a 5 mg/ml solution of
2,5-dihydroxybenzoic acid (acetonitrile, 0.1% aqueous trifluoroacetic
acid; 1:2). After drying, the -cyano-4-hydroxycinnamic acid-contain-
ing preparations were recrystallized with 0.3 l of ethanol, acetone,
0.1% aqueous trifluoroacetic acid (6:3:1).
MALDI-TOF mass spectra were acquired on an Autoflex (Bruker
Daltonics, Coventry, UK) operated in the positive ion mode using a
nitrogen laser emitting at 337 nm. Protein mass spectra were ac-
quired in the linear mode, whereas digest spectra were recorded in
reflectron mode for enhanced mass resolution. To avoid detector
saturation low mass material was deflected. The detector voltage was
1.75 kV. All other parameters were set for an optimized mass reso-
lution. Usually the mass spectra from 200 laser shots were averaged.
Linear MALDI-TOF mass spectra were externally calibrated using the
signals from bovine insulin, bovine ubiquitin, equine cytochrome c,
and bovine  lactalbumin. MALDI spectra of tryptic digests were
internally mass-corrected using trypsin autolysis fragments.
PSD MALDI-TOF MS—For PSD MALDI analysis, the pulsed ion
deflector on the Autoflex was set to allow the selection of the precur-
sor ion in a 5-Da mass window. Pulsed ion extraction of 80 ns was
used for enhanced spectral resolution. The reflector voltage was
stepped from a maximum of 20 kV depending on the mass of the
precursor ion down to 0.59 kV in a maximum of 18 segments to focus
metastable fragments on the detector. The spectra obtained at each
reflector voltage setting were pasted together in XMASSTM using a
calibration file from the PSD fragments of the adrenocorticotropic
hormone clip 18–39. The mass assignment of fragments was per-
formed in XMASSTM using an annotation macro for PSD spectra.
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Nano (n)-ESI-MS—The peptide samples were desalted using C18
ZipTips as described above with the exception that formic acid was
used instead of trifluoroacetic acid as an ion-pairing agent. The
samples were directly infused into a LCQ Deca XP ion trap mass
spectrometer (Thermo Finnigan, San Jose, CA) using PicoTip nano-
capillaries (New Objective, Woburn, MA). Each ion species was iso-
lated for an MS2 experiment using an isolation width of 2–3 mass
units, and the normalized collision energy was set between 30 and
40%.
N-terminal Sequencing by Edman Degradation—N-terminal se-
quences were provided as a service by Dr. J. Keen of the protein
sequencing facility at the University of Leeds using a Procise 494
gas-phase/liquid-pulse sequencer (Applied Biosystems, Foster City,
CA).
Carbohydrate Staining—To identify carbohydrates after SDS-
PAGE, a glycoprotein detection kit (Sigma) was used in accordance
with the procedures recommended by the manufacturer.
RESULTS
Isolation of HAF—In a previous study we fractionated pro-
tein molecules from the urinary hCG preparation CG-10
(Sigma) on a Sephadex G-100 column where hCG eluted first
and hCGcf appeared in later fractions. An unidentified pro-
tein complex (HAF) eluted closely to hCGcf (data shown in
previous publication) (27). Those fractions were pooled to-
gether and assayed for total protein (530 g/ml), hCG (not
detected, 1% cross-reactivity), hCG (not detected, 1%
cross-reactivity), and hCGcf (1,200 pmol/ml, 2% cross-
reactivity). SDS-PAGE of HAF showed protein bands at 27,
19, and 10 kDa under non-reducing conditions; under reduc-
ing conditions two bands were observed at 15 and 10 kDa
(Fig. 1).
Molecular Identification of HAF—Polypeptides were eluted
from individual gel bands produced under both non-reducing
and reducing conditions and subjected to MALDI-TOF MS.
Analysis of intact HAF components eluted from the non-
reducing SDS-PAGE bands showed no MALDI signals for the
27-kDa gel band, two signals at m/z 15,770.5 (singly charged
ion) and 7,887.1 (doubly charged ion) for the 19-kDa band,
and two signals at m/z 11,361.5 (singly charged ion) and
5,684.0 (doubly charged ion) for the 10-kDa band (Fig. 1,
A–C). In-gel tryptic digestion of the separated HAF compo-
nents on non-reducing SDS-polyacrylamide gels followed by
MALDI-TOF MS and a Mascot data base search (www.ma-
trixscience.com) identified two polypeptides included within
the 27-kDa gel band that were derived from placental trans-
forming growth factor- (pTGF-) and bikunin and will be
referred to here as metabolite (m)-pTGF- and metabolite-
bikunin (m-bik), respectively (Fig. 1D). Moreover the 19-kDa
gel band contained only m-bik (15.8 kDa with MALDI-TOF
MS) (Fig. 1E), whereas the 10-kDa gel band contained m-
pTGF- (11.4 kDa by MALDI-TOF MS) (Fig. 1F). Details of
the tryptic mass mapping can be seen in Table I, and Fig. 2
FIG. 1. SDS-PAGE and MALDI-TOF MS of HAF preparation. SDS-PAGE was performed under non-reducing and reducing conditions with
boxed areas indicating the excised bands that were subsequently subjected to MALDI-TOF MS. A–C, eluted intact proteins as determined by
MALDI-TOF MS. D–F, MALDI-TOF MS of tryptic digests with all identified signals being labeled. The coding for the mass labels can be found
in Table I. Identical results were obtained with polypeptides eluted from reducing SDS-polyacrylamide gels (data not shown). P, m-pTGF-
fragments; B, m-bik fragments; ox, oxidation; T, trypsin autolysis fragments.
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shows the full amino acid sequences of m-bik and m-pTGF-.
Identical results with the 19- and 10-kDa gel bands under
non-reducing conditions were obtained from polypeptides
eluted from reducing SDS-polyacrylamide gel bands at 15
and 10 kDa, respectively (data not shown).
PSD MALDI-TOF and nESI-MS were performed with some
selected tryptic fragments to confirm peptide identifications.
For example, PSD MALDI-TOF MS confirmed the presence of
m-bik within the 19-kDa (non-reducing SDS-PAGE) and 15-
kDa (reducing SDS-PAGE) gel bands by generating charac-
teristic fragmentation of the major peptide ion at m/z 1,213.6
(Fig. 3). Furthermore nESI-MS confirmed the identity of some
tryptic peptides of m-pTGF- within the 10-kDa gel bands
(non-reducing and reducing SDS-PAGE), for example at m/z
1,814.9 (Fig. 4).
To determine the N-terminal position of the HAF compo-
nents, Edman degradation experiments were performed on
polypeptides eluted from reducing SDS-polyacrylamide gels.
FIG. 2. Amino acid sequences of m-
bik and m-pTGF-. A, m-bik (129 amino
acids); B, m-pTGF- (112 amino acids).
Numbers indicate amino acid positions
on the precursor proteins. Gray areas
represent tryptic peptides identified in
Table I. Italics, N-terminal sequence; *,
N-linked glycosylation site.
TABLE I
Identification of tryptic fragments of HAF
HAF tryptic fragments shown in Fig. 1 were identified by using the Mascot search engine. P signals were obtained from m-pTGF-, and B
signals were obtained from m-bik. The N-terminal sequences of m-bik and m-pTGF- as shown in Table II are bold.
Peptide no. Range Amino acid sequence
M  H
Mass accuracy
Calculated Observed
ppm
m-bik
B1 1–3 VTK 347.23
B2 4–4 K 147.11
B3 5–23 EDSCQLGYSAGPCMGMTSR 2,106.83 2,106.83 0
B4 24–52 YFYNGTSMACETFQYGGCMGNGNNFVTEK 3,347.35
B5 53–59 ECLQTCR 966.41 966.42 10
B6a 60–70 TVAACNLPIVR 1,213.67 1,213.69 16
B7 71–74 GPCR 489.22
B8 75–86 AFIQLWAFDAVK 1,408.76
B9 87–88 GK 204.13
B10 89–103 CVLFPYGGCQGNGNK 1,670.74 1,670.71 18
B11 104–108 FYSEK 673.32
B12 109–111 ECR 464.19
B13a 112–126 EYCGVPGDGDEELLR 1,708.75 1,708.77 12
B14 127–129 FSN 367.16
B2b B3 4–23 KEDSCQLGYSAGPCMGMTSR 2,234.93 2,234.92 4
B11b B12a 104–111 FYSEKECR 1,118.49 1,118.51 18
m-pTGF-
P1 1–2 AR 246.16
P2 3–13 NGDHCPLGPGR 1,179.53
P3 14–16 CCR 495.18
P4 17–21 LHTVR 625.38 625.37c 16
P5a 22–37 ASLEDLGWADWVLSPR 1,814.91 1,814.90 6
P6a 38–53 EVQVTMCIGACPSQFR 1,882.87 1,882.89 11
P7 54–62 AANMHAQIK 983.51 983.50 10
P8 63–67 TSLHR 613.34 613.31c 49
P9a 68–91 LKPDTVPAPCCVPASYNPMVLIQK 2,698.34 2,698.35 4
P10a 92–107 TDTGVSLQTYDDLLAK 1,739.87 1,739.88 6
P11 108–112 DCHCI 704.25 704.26c 14
P10b P11 92–112 TDTGVSLQTYDDLLAKDCHCI 2,425.10 2,425.09 4
a Tryptic peptides were also observed in the 27-kDa gel band from non-reducing SDS-polyacrylamide gels (Fig. 1D).
b Indicates a missed cleavage.
c Low molecular weight ions not shown in Fig. 1.
Molecular Identification of HAF
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The obtained N-terminal sequence tags were subjected to a
protein BLAST search (www.ncbi.nlm.gov/BLAST) for short
and nearly exact matches in protein and gene data bases.
They generated significant sequence alignments with bikunin
and pTGF- for polypeptides eluted from reducing SDS-poly-
acrylamide bands at 15 and 10 kDa, respectively (Table II).
Carbohydrate Detection in HAF Preparation—Both bikunin
and pTGF- are known to contain carbohydrate structures
(30, 31). Their presence on both m-bik and m-pTGF- was
investigated, although carbohydrate moieties were not ex-
pected to be found on m-pTGF- (see “Discussion”). Carbo-
hydrates were detected on SDS-PAGE bands that were run
under non-reducing conditions. The SDS-PAGE protein band
corresponding to m-bik at 19 kDa stained positively for car-
bohydrates, whereas all other bands were negative (Fig. 5).
Tryptic digest MALDI-TOF analysis of m-bik resulted in an
incomplete map of bikunin structure between amino acids
224 and 352 (Fig. 2A). In particular, a sequence spanning
amino acids 247–275 (which includes the glycosylation site
Asn250) was not observed in the spectrum. This could indicate
that glycosylation structures are still present and therefore
contribute to the overall mass of m-bik (15.8 kDa). Further
studies are necessary to determine the entire structure. This
contrasts with m-pTGF- in which almost the entire structure
between amino acids 197 and 308 was identified by peptide
mass mapping (Fig. 2B).
Mass Spectrometric Analysis of Urinary Pregnancy hCG
Preparations—The anti-HIV-KS active clinical grade urinary
hCG preparations CG-10 (Sigma), Pregnyl (Organon), and
Profasi (Serono) were subjected to MALDI-TOF MS and com-
pared with the MALDI spectra of HAF (Fig. 6). Within the low
molecular mass range (m/z 6–18,000), all commercial prepa-
rations gave a resolved signal pattern of the -subunit of hCG
(hCG) resulting from glycoform heterogeneity. Furthermore
doubly charged hCG signals were also observed (Fig. 6, A
and C). In addition, the Pregnyl preparation exhibited consid-
erable levels of hCGcf. All preparations contained a signal at
approximately m/z 11,400. A signal at approximately m/z
15,800 was only present in the HAF preparation; however, as
it was of low abundance it might have been suppressed in the
MALDI spectra of other hCG preparations where more total
protein (mainly hCG) was present (Fig. 6, A–C). Furthermore
an intense signal at approximately m/z 6,200 in the HAF
preparation was also observed as a major species with Preg-
nyl and as a low abundance signal with CG-10, but it was not
present in Profasi.
DISCUSSION
Proteins associated with pregnancy urine and hCG prepa-
rations have been shown to reduce Candida albicans patho-
genesis, induce apoptosis in KS cells, and inhibit HIV replica-
tion (22–26). The active protein components have been
reported previously to be an 18-kDa RNase closely homolo-
gous to eosinophil-derived neurotoxin (22, 23), a 14-kDa hu-
FIG. 3. PSD MALDI-TOF MS of m-bik. The 1,213.6-Da m-bik
tryptic peptide B6 (Table I) was selected for PSD MALDI-TOF MS.
Only the y and b ion series are labeled, and the ion coverage is
indicated in the sequence string at the top of the figure.
FIG. 4. nESI-MS of m-pTGF-. The 1,814.9-Da m-pTGF- tryptic
peptide P5 (Table I) was selected for nESI-MS. The sequence at the
top of the figure indicates the ion coverage for the peptide. Only the
y and b ions are labeled in the spectrum.
TABLE II
N-terminal sequences of m-bik and m-pTGF-
Sequences were obtained by Edman degradation on excised pro-
tein bands from SDS-polyacrylamide gels under reducing conditions.
X, unidentified residue; underlined residues, uncertain assignment.
Gel band
molecular mass
N-terminal sequence Polypeptide
kDa
15 VTKKEDS(S/C)QL m-bik
10 ARNGD(D/H)XPLG m-pTGF-
Molecular Identification of HAF
988 Molecular & Cellular Proteomics 4.7
 by on O
ctober 27, 2009 
w
w
w
.m
cponline.org
D
ow
nloaded from
 
man lysozyme C (24), an RNase A (23 kDa), and a urinary
RNase U (18 kDa) (24). In some cases it has simply been
described as a protein complex named HAF that was com-
posed of 15–30- and 2–4-kDa polypeptides (25, 26). The
urinary hCG preparation CG-10 (Sigma) is known to be rich in
these hCG-associated bioactive polypeptides. The aim of this
study was to use modern mass spectrometry to identify these
urinary hCG-associated proteins that contaminate pharma-
ceutical preparations of hCG known to have anti-HIV-KS
activity (25, 26).
Tryptic mass mapping by MALDI-TOF MS, PSD MALDI-
TOF MS, nESI-MS, and N-terminal sequencing of isolated
HAF identified two polypeptides to be fragments of pTGF-
(m-pTGF-, 11.4 kDa) and bikunin (m-bik, 15.8 kDa) (Figs. 1,
3, 4, and 6 and Tables I and II). There was no evidence for the
presence of RNase A, RNase U, eosinophil-derived neuro-
toxin, or lysozyme C.
pTGF- is also known as macrophage inhibitory cytokine-1
(MIC-1), growth differentiation factor-15, placental bone mor-
phogenic protein, prostate differentiation factor, and neuregu-
lin-1. It has a mature intact polypeptide mass of 12.5 kDa
(Swiss-Prot entry number Q99988, www.expasy.ch) and, by
homology to other TGF-s, forms a disulfide-linked ho-
modimeric protein (32). pTGF- first appeared in the literature
as MIC-1, an autocrine regulatory molecule of macrophage
cells (31). It was later shown that the human placenta pro-
duced MIC-1 with elevated levels found in maternal serum
(33). Antitumorigenic activity of pTGF- was first demon-
strated by Li et al. (34) who found that its overexpression
could induce cell cycle arrest and apoptosis in breast tumor
cells in vitro. Subsequent studies showed that its down-reg-
ulation could decrease cell cycle arrest and apoptosis in
human mammary carcinoma cells (35) and increase the inci-
dence of benign prostatic hyperplasia (36). In vitro experi-
ments on cancer cells showed that pTGF- could reduce cell
adhesion followed by cell detachment and induce apoptosis
(37, 38). However, some studies have proposed a positive
relationship between pTGF- expression and tumor progres-
sion in colorectal carcinoma (39) as well as gastric tumor
tissues (40). This is consistent with the bifunctional role of
TGF-, which induces mesothelial cell growth while inducing
epithelial cell apoptosis (6).
It is important to bear in mind that what has been detected
in these urinary hCG preparations is a fragment of the pTGF-
monomer not the mature protein. Thus any anti-HIV-KS ac-
tivity is not likely to be via receptor activation but most prob-
ably via antagonist mechanisms. Interestingly this is consist-
ent with a previous suggestion that hCG fragments blockade
the TGF- receptor complex by virtue of their cysteine knot
growth factor structural homology with TGF- (6). Obviously if
this were the case, high levels of a monomeric fragment of
pTGF-would have greater antagonistic properties. However,
it is highly probable that the anti-HIV-KS activity of these
preparations is not solely due to m-pTGF-. Clinical studies
have clearly shown that effective anti-HIV-KS treatment is
only achievable when an antiviral replication agent is used in
combination with a protease inhibitor (41).
Bikunin is a proteinase inhibitor containing two Kunitz do-
mains (30). It has various synonyms: inter--trypsin inhibitor
light chain, urinary trypsin inhibitor, acid-stable trypsin inhib-
itor, mingrin, urinastatin, and ulinastatin. It is initially ex-
pressed as the 1-microglobulin/bikunin precursor, which is
post-translationally modified to contain asparagine (N-)-linked
glycosylation moieties and a very large chondroitin chain. The
mass of the unmodified amino acid chain is 16.0 kDa (Swiss-
Prot entry number P02760, www.expasy.ch), whereas its in-
tact mass is 25–26 kDa depending on the structure of the
post-translational chondroitin and N-linked glycosylation
chains (30). Aside from its established proteinase inhibitor
activity, bikunin also functions as a growth factor in fibroblasts
and as an inflammatory acute phase marker protein (30). One
study has shown that certain recombinant forms of bikunin
can have an inhibitory effect on HIV-1 infectivity in vitro (42). In
cancers, its expression by human glioblastoma cells can
cause suppression of tumor invasion (43), whereas addition of
bikunin to human chondrosarcoma cell cultures blocks cell
spreading (44).
Although we only detected a fragment of bikunin (m-bik) in
these preparations, it is very likely that what remains are
active protein Kunitz inhibitor domains. The large m-bik 15.8-
kDa fragment contains both Kunitz domains of bikunin, and
domain I is the only domain to contain an N-linked carbohy-
drate structure (amino acid position 250 on the precursor
molecule) (30). An O-linked chondroitin sulfate chain, consist-
ing of disaccharide-repeating units, is attached on the N-
terminal extension of bikunin but is not found within m-bik
(amino acid position 215 of the precursor molecule) (30). In the
present study, m-bik was shown to be glycosylated. In con-
trast, although pTGF- contains an N-linked glycosylation site
at amino acid position 70 of the intact precursor molecule
(31), there was no evidence for any carbohydrate structures
being present on m-pTGF- (Fig. 5). This is consistent with
the fact that m-pTGF- was truncated at amino acid 197 on
the precursor polypeptide, whereas m-bik was truncated at
amino acid 224 on the precursor polypeptide; therefore m-bik
retained a possibly metabolized N-linked glycosylation at
amino acid position 250 (Fig. 2A). Bikunin carbohydrates play
FIG. 5. Carbohydrate detection in the HAF preparation. Carbo-
hydrate detection was performed after SDS-PAGE of HAF under
non-reducing conditions. Magenta bands are positive for sugar moi-
eties. A, markers; B, HAF preparation; C, horseradish peroxidase.
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a central role in determining its functions, and it is thus pos-
sible that m-bik retains its Kunitz domain protease inhibitory
properties (45).
It is also significant that MALDI-TOF MS analysis of HAF
(Fig. 6D) revealed the presence of a 6.2-kDa trypsin resistant
component that was not visualized on the gels. It is possible
FIG. 6. MALDI-TOF MS of different hCG preparations. A, CG-10 (Sigma); B, Pregnyl (Organon); C, Profasi (Serono); D, HAF preparation.
The spectra focus on the mass region between 6 and 18 kDa. hCGwas observed in A, B, and C but is omitted here for clarity. The mass region
from 8.5 to 15 kDa in B is expanded 10.
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that, due to its mass resemblance and loss after extensive
denaturation during SDS-PAGE, this might have been a fur-
ther degradation fragment of bikunin consisting solely of
Kunitz domain II. A theoretical mass for a bikunin Kunitz
domain II fragment, between amino acids 285 and 340 of its
precursor protein, is 6,176 Da and therefore matches the
unknown peptide detected to within 1 Da of mass accuracy.
An alternative candidate trypsin inhibitor exists in the litera-
ture. A 6.2-kDa polypeptide protein with antiprotease activity
was isolated from the urine of a patient with ovarian cancer
(46). It was termed tumor-associated trypsin inhibitor (TATI)
but is also known as pancreatic secretory trypsin inhibitor
(47). TATI has an intact mass of 6,247 Da (Swiss-Prot entry
number P00995, www.expasy.ch), and thus the polypeptide
observed at m/z 6,175 in this study (Fig. 6D) could be a
metabolic product of TATI. Its expression has also been noted
in pregnancy where TATI is produced at levels similar to those
in cancerous conditions (48).
Clearly this study is in conflict with previous data, which
propose RNase and lysozyme molecules as the active anti-
HIV-KS contaminant components of pregnancy urine and uri-
nary hCG preparations (22–24). In an editorial Darzynkiewicz
(7) pointed out the considerable methodological and theoret-
ical flaws in the previously reported studies of the anti-KS
factor found in urinary hCG preparations. Indeed he stated
that identification of this anti-KS factor contaminating hCG
was essential for further progress in the clinical application of
hCG. The proteomic mass spectrometric techniques used in
this study are far more discriminatory than immunoblotting
and catalytic enzymatic assays used in other reports. Indeed
none of the previously proposed molecules were observed in
any of the examined hCG preparations.
In 1998 a publication by Lunardi-Iskandar et al. (25) stated
that identification of the active moiety(ies) of HAF from clinical
grade pregnancy urine hCG preparations was one of the high
priorities for the initiation of clinical trials where the biological
properties of the recognized components could be investi-
gated. We have now identified the anti-HIV-KS proteins
closely co-eluting with hCGcf from the pregnancy urine hCG
preparations CG-10 (Sigma), Pregnyl (Organon), and Profasi
(Serono) as m-pTGF-, m-bik, and possibly a metabolic prod-
uct of TATI. In general terms, this concurs with the original
studies of Lunardi-Iskandar et al. (25) in which they proposed
HAF to be composed of several polypeptides ranging from
2–30 kDa. Now that we have identified the contaminant pro-
teins in commercial hCG preparations with anti-HIV-KS activ-
ity, the possible role of hCG in HIV-KS treatment can be
thoroughly investigated.
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